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CORRECTION Open Access
Correction to: Therapeutic novelties in
migraine: new drugs, new hope?
Thien Phu Do, Song Guo and Messoud Ashina*
Correction to: J Headache Pain (2019) 20:37
https://doi.org/10.1186/s10194-019-0974-3
After publication of the original article [1], the authors
have notified us that the row corresponding to the
“Alniditan” drug shouldn’t have been included in
Table 1. Table 1 should therefore be presented as below:
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Table 1 Overview of ditans in alphabetical order
Drug Status
Lasmiditan (COL-144) Phase III clinical trials
LY-334370 Development terminated
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